Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide-Pulsed Dendritic Cell Vaccine + IL-2 in Metastatic Melanoma
NCT00006113Phase 2Terminated
- Sponsor
- University of Southern California
- Start
- Jun 1999
- Primary completion
- May 2003
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Intus in melanoma, sponsored by University of Southern California. Primary endpoints: Clinical Response Rate, Immune Response and 1 more. Started Jun 1999; status: terminated.
02
Drugs
Intus
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00006113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006113.